MAP2K7 and non-small cell lung carcinoma: The combination of BRAF and MEK inhibitors demonstrated higher overall response and median PFS than dabrafenib monotherapy, establishing the combined therapy as a standard treatment in patients with advanced or metastatic NSCLC with BRAF V600E driver mutations.